Price Prediction

Eli Lilly (LLY) Stock Price Prediction: Lilly pulls back toward support as analysts stay constructive

Eli Lilly (LLY) is trading at $1,369.97, below its short-term moving averages after a 2.52% 24-hour decline, but the broader structure still shows a constructive trend above the 50-day average. Fre...

Eli Lilly (LLY) Stock Price Prediction: Lilly pulls back toward support as analysts stay constructive

What the tape is saying

Eli Lilly (LLY) is easing off recent highs rather than breaking down outright. The stock is at $1,369.97, down 2.52% over 24 hours, and it has slipped under the 7-day SMA of $1,414.69, the 20-day SMA of $1,407.70 and the 12-day EMA of $1,403.69. But it remains above the 50-day SMA of $1,303.14, which keeps the medium-term trend intact.

That matters because this looks more like a digestion phase than a trend failure. The volume backdrop supports that read: activity is running at 0.51x the 5-day average, which points to a low-volume pullback rather than an aggressive liquidation.

Fundamental backdrop stays strong

The company’s latest reported quarter was a clear step up. According to Eli Lilly’s October 29, 2026 release, third-quarter revenue rose 39% year over year to $24.4 billion, driven primarily by Mounjaro and Zepbound. Reported EPS increased 16% to $7.22, while non-GAAP EPS rose 7% to $7.48. Lilly also lifted the midpoint of its 2026 full-year revenue guidance by $5.5 billion to a range of $91.0 billion to $92.0 billion, which gives investors a stronger operating base to lean on.

That backdrop is why the street remains constructive despite the share-price strength already on the chart. RBC Capital reiterated an Outperform rating and a $1,600 price target on November 17, saying the December 7 Innovation Day is strategically important for highlighting growth beyond obesity. Barclays, on November 16, raised its target to $1,550 from $1,400 and kept an Overweight rating. StockAnalysis also cites a consensus Buy rating from 31 analysts with an average target of $1,469, which sits above the current price but below the more bullish house calls.

Technical setup: near support, not broken

The chart is sitting close to the lower half of its recent range. Bollinger Bands place the lower band at $1,346.09 and the middle band at $1,407.70, with %B at 0.1938, which signals price is trading near lower-band support. The pivot point is $1,387.60, immediate support is $1,351.64, and strong support sits at $1,333.32. On the upside, immediate resistance is $1,405.92 and stronger resistance is $1,441.88.

Momentum is mixed, not bearish in a clean trend sense. The 14-day RSI is 48.74, which is neutral. The MACD histogram is flat at 0.0000, while the stochastic readings are low at 23.53 for %K and 18.82 for %D, suggesting the stock is stretched enough to keep bears interested but not yet in a decisive breakdown.

Derivatives positioning points to caution, not panic

On Binance perpetual futures, the 8-hour funding rate is neutral at 0.0000%, so there is no clear leverage skew from funding alone. Open interest is 2,195.55 contracts, with daily open interest value at $3.25 million and a 24-hour OI increase of 3.48%, which shows positions are rebuilding even as price softens.

The long/short mix leans cautious. Binance global accounts are 45.4% long and 54.6% short, while top-trader accounts are 42.8% long and 57.2% short. The taker buy/sell ratio of 0.5787, with 39 buy volume versus 68 sell volume, shows aggressive selling pressure in the near term. That combination usually argues for patience: sellers have the tape right now, but the broader trend has not yet been cleanly damaged.

Levels to watch

The immediate test is whether LLY can hold $1,351.64 and then $1,333.32. If those levels give way, the chart opens up toward the 50-day average at $1,303.14. On the upside, reclaiming $1,387.60 and then $1,405.92 would help stabilize the short-term picture and put $1,441.88 back in play.

The core question is simple: can Lilly’s strong earnings and guidance carry the stock through a period of consolidation, or does the recent run leave it vulnerable to a deeper reset? Right now the evidence says consolidation, not capitulation.

Sign in to save this article Free account: build your research collection and return to read it anytime.